Cell & Gene Therapy

too many options
Biotech

Adaptimmune questions own longevity, axes 2 preclinical assets

Adaptimmune is cutting preclinical programs and evaluating strategic options in efforts to save cash.
Gabrielle Masson Mar 20, 2025 2:04pm
Yellow arrow going opposite direction as white arrows

BioNTech passes on Autolus CAR-T amid pipeline prioritization

Mar 20, 2025 9:11am
Healthy foods surrounding chalk drawing of gut

Edited T cells allow gluten-sensitive mice to eat grains

Mar 20, 2025 7:16am
Abstract modern white spiral clock dial with roman and arabic numerals

Cell therapy biotech axes cancer trial, turns to autoimmune

Mar 19, 2025 5:35pm
layoffs cuts workforce reduction chairs boxes fired

UK cell programming biotech lays off 25% of staff

Mar 19, 2025 3:05pm
Cargo shipping containers lost in ocean

Cargo jettisons remaining assets, cuts 90% of staff

Mar 18, 2025 5:54pm
More News

Another NIH leader is out amid Trump admin shake-up: Stat

Mar 18, 2025 3:45pm

Arbor sails into rocky gene editing waters with $74M

Mar 18, 2025 6:30am

Kiromic furloughs 'substantially all' workers amid cash crunch

Mar 18, 2025 5:42am

AstraZeneca goes in vivo, pens $1B deal for lentiviral biotech

Mar 17, 2025 7:40am